Grifols (GIKLY) Payables (2010 - 2025)
Grifols (GIKLY) reported Payables of $1.3 billion for Q4 2025, up 8.45% on a YoY basis from $1.2 billion in Q4 2024, and up 8.45% quarter-over-quarter from $1.2 billion in Q4 2024.
Grifols (GIKLY) Payables (2010 - 2025) Analysis & Trends
Grifols has reported Payables for 16 years, with the latest figure at $1.3 billion in Q4 2025.
- For the quarter ending Q4 2025, Payables rose 8.45% year-over-year to $1.3 billion; the trailing twelve-month figure through Dec 2025 stood at $1.3 billion (up 8.45% YoY), and the FY2025 full-year result was $1.3 billion, up 8.45% from the prior year.
- Payables for Q4 2025 stood at $1.3 billion, up from $1.2 billion in the prior quarter.
- The five-year high for Payables was $1.3 billion in Q4 2025, with the low at $719.5 million in Q4 2021.
- Historically, Payables has averaged $982.1 million across 5 years, with a median of $885.4 million in 2023.
- Annual changes were most pronounced in 2021 — Payables climbed 0.31% — and 2024, when it jumped 35.53%.
- Grifols' Payables stood at $719.5 million in 2021, then climbed by 11.73% to $803.9 million in 2022, then advanced by 10.14% to $885.4 million in 2023, then surged by 35.53% to $1.2 billion in 2024, then gained by 8.45% to $1.3 billion in 2025.
- The last three Payables figures came in at $1.3 billion (Q4 2025), $1.2 billion (Q4 2024), and $885.4 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -26.13 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 5.03 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 27.92 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 33.77 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 6.01 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 2.94 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 645.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 4.51 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 4.23 Bn |
| 10 | Grifols | - | - | - | 1.30 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.30 Bn |
| Dec 31, 2024 | 1.20 Bn |
| Dec 31, 2023 | 885.45 Mn |
| Dec 31, 2022 | 803.92 Mn |
| Dec 31, 2021 | 719.55 Mn |
| Dec 31, 2020 | 717.30 Mn |
| Dec 31, 2019 | 644.08 Mn |
| Dec 31, 2018 | 641.33 Mn |
| Jun 30, 2018 | 509.83 Mn |
| Dec 31, 2017 | 498.17 Mn |
| Jun 30, 2017 | 434.13 Mn |
| Dec 31, 2016 | 660.71 Mn |
| Sep 30, 2016 | 436.40 Mn |
| Jun 30, 2016 | 452.56 Mn |
| Dec 31, 2015 | 449.39 Mn |
| Sep 30, 2015 | 391.32 Mn |
| Jun 30, 2015 | 406,464.33 |
| Mar 31, 2015 | 430.85 Mn |
| Dec 31, 2014 | 549.47 Mn |
| Dec 31, 2013 | 372.42 Mn |